Sun Pharmaceuticals has joined several pharmaceutical companies at a White House ceremony to announce agreements with the US government aimed at prioritising access to affordable medicines for millions of American patients.

As part of its agreement, Sun Pharma will extend Most Favored Nation (MFN) pricing to state Medicaid programs. The company also commits to MFN pricing for future innovative medicine launches. The agreement recognises Sun Pharma’s investment in the US market by delaying Section 232 tariffs on innovative pharmaceutical products for over 2 years. Further terms of the agreements remain confidential.

Rick Ascroft, CEO, Sun Pharma, North America, said, “Our mission is to reach people and touch lives by providing quality medicines across a patient’s entire treatment journey, from consumer health products to generics to innovative medicines, who represented the company at the White House. The United States is a key area of investment and expansion for Sun Pharma across clinical development, sales and marketing, and both API and finished products manufacturing. We are proud to play our part in delivering the medicines that millions of American patients count on every day.”

The company initially built its US presence on a foundation of high-quality generics followed by an increasing emphasis on innovative and specialty medicines. The company ranks second by prescriptions in US dermatology and continues to expand across dermatology and immunology, cutaneous oncology, and ophthalmology, complementing a robust consumer health products and generics business.

The US is Sun Pharma’s largest market for innovative medicines and a cornerstone of its long-term growth strategy, generating approximately 27 percent of the company’s global revenue. Commitment to the US market was further underscored earlier this year through the company's definitive agreement to acquire Organon and Co. at an enterprise value of USD 11.75 billion–a milestone that reflects Sun Pharma's continued investment in American patients, healthcare providers, and communities.

Sun Pharma remains focused on its core mission of expanding access to high-quality, affordable medicines for patients in the US and around the world.